Injection-grade E. coli antigen concentrates processed as aqueous suspensions are brought into a sterile mixing vessel after inactivation and buffer exchange through tangential-flow filtration. The resulting biomass may contain whole bacterial cells or subunit fractions, which determines whether sterile filtration is operationally possible: whole-cell antigen suspensions are not passed through 0.22 µm filter capsules because the cells exceed the membrane pore rating and would collect prematurely. Instead, buffer components and adjuvant phases are sterilized separately by autoclave or filtration, while the antigen stream remains aseptically closed from inactivation to final filling under an ISO 14644-1 Class 7 environment in the critical zone. Adsorption onto aluminum hydroxide or a mineral-oil emulsion is carried out in a jacketed vessel at 4–8°C; low-shear impeller speeds are used because rotor-stator systems above 6,000 rpm can generate localized heating and cell-wall fragment release. No claim regarding antigen binding is considered valid without monitoring free antigen in the supernatant by ELISA; batch-to-batch variance in adsorption efficiency is a recognized production bottleneck. The final liquid suspension is checked for sterility according to Ph. Eur. 2.6.1, bacterial endotoxins according to Ph. Eur. 2.6.14, and uniformity of doses according to Ph. Eur. 2.9.40 when it is packed in multi-dose containers. Aseptic filling uses peristaltic pump lines with single-use tubing; the fill volume tolerance is limited to ±2.0% of label claim for multi-dose vials with a 10-dose presentation to avoid under-delivery at the final dose. If the product is frozen during storage, emulsion adjuvants may separate and antigen may desorb, so storage at 2–8°C with continuous temperature logging is typically used.

Adsorption kinetics are not instantaneous. The jacketed vessel is held under slow agitation for 12–24 h at 4–8°C before final adjuvant concentration is fixed; the endpoint is based on free-antigen assay rather than a preset mixing time. Batch-to-batch variance in bacterial cell density, endotoxin level, and surface hydrophobicity changes the amount of adjuvant required; therefore the loading ratio is re-evaluated for each API lot. In-process pH is checked with a calibrated electrode at 15-minute intervals during the first hour because pH drift above 7.4 can weaken antigen-adjuvant association. The filled vials are inspected for subvisible particles by light obscuration using Ph. Eur. 2.9.19 if the presentation is intended for parenteral use; particle counts above the specified limit are a release failure. Terminal sterilization by autoclave is excluded because whole-cell antigen is heat-labile, so the entire operation from vial washing to capping is performed under aseptic conditions with environmental monitoring plates and contact plates under ISO 14644-1 and EU GMP Annex 1. The processing window is narrow: pH outside 6.0–7.4 or temperature above 8°C during mixing can produce free-antigen loss and variable immunogenicity in the final dose.

Does residual moisture above 2.0% w/w accelerate aggregation in freeze-dried E. coli antigen cakes?

Freeze-drying of E. coli antigen API for injection reconstitution must be controlled around three measurable transitions: cake collapse, residual moisture, and reconstitution time. The formulation is first frozen on stainless-steel shelves to a product temperature below its collapse point; for many sucrose- or trehalose-stabilized bacterial antigen matrices, primary drying is conducted with shelf temperature between -30°C and -15°C and chamber pressure between 0.1 mbar and 0.3 mbar, but published data for this specific E. coli antigen configuration is limited. The product temperature is therefore determined by freeze-drying microscopy rather than assumed from a generic formulation. If the product temperature exceeds the glass transition temperature of the maximally concentrated freeze concentrate, cake shrinkage and collapsed pores increase residual moisture by trapping water vapor, and reconstitution may exceed 120 s after adding water for injection. Karl Fischer titration according to Ph. Eur. 2.5.32 is used on stoppered vials immediately after unloading. Batches with vial-to-vial residual moisture above 2.0% w/w are held for additional secondary drying under reduced shelf pressure because free water above this threshold increases molecular mobility of surface proteins and accelerates aggregation upon storage at 2–8°C.

At the end of secondary drying, the vials are backfilled with nitrogen to 0.8 bar absolute pressure before stoppering to reduce oxidative degradation of surface antigens. The residual gas oxygen content is verified below 2.0% by a headspace analyzer; vials with oxygen above this limit are rejected because oxygen can promote antigen aggregation during storage. The dried cake is not a single-phase system; it contains crystalline bulking agents, amorphous stabilizer regions, and antigen-rich domains. Moisture within the amorphous phase is the critical control because the plasticizing effect of water lowers glass transition and shortens the shelf life of the injection powder. Particle size distribution after reconstitution is measured by laser diffraction according to Ph. Eur. 2.9.31; the D50 value must not increase by more than 1.5-fold compared with the pre-freeze-drying control, otherwise the powder is considered inadequately dispersed. When injection powders are made for multi-dose vials, the powder must reconstitute to a suspension that passes the syringeability test through a 21-gauge needle; the test is performed with a 5 mL syringe at a constant hand pressure.

Tablet incorporation of E. coli antigen powders introduces a compression stress conflict that does not exist in parenteral or liquid flows. The oral tablet format is used where solid-dose accuracy and field stability are required, but the compaction event can shear antigen-coated granule surfaces, reject fine particles into the press feed frame, and produce capping when the granule fracture mode is excessively brittle. Direct compression is limited to formulations in which the antigen powder and filler have closely matched bulk densities and particle-size distributions; otherwise the press feed frame segregates by size and density. Tableting trials are run on an instrumented rotary press with upper and lower punch force transducers, and compaction force is profiled against tablet hardness measured by Ph. Eur. 2.9.8. The relationship between compaction force and antigen recovery is not assumed from chemical drugs because inactivated bacterial antigen may lose ELISA-reactive epitopes under localized friction. If acceptable hardness cannot be achieved below the point of antigen loss, dry granulation with roll compaction is preferred over wet massing because water addition can activate residual enzymatic activity and increase microbial-derived impurities.

Dry granulation by roll compaction is specified when direct compression cannot achieve a balance between hardness and antigen recovery. The powder is passed through a roller compactor with roll gap 2.0 mm and roll speed adjusted to produce ribbons with density above 0.7 g/cm³; ribbons are milled through a 1.25 mm screen and the resulting granule fraction is characterized by bulk and tapped density per Ph. Eur. 2.9.34. If the fines fraction below 75 µm exceeds 30%, segregation and capping probability increase. Tablet press feed frame speed and die table speed are matched to avoid weight variability above ±3.0% during scale-up from 5 kg to 100 kg batches. Tablets are designed to disintegrate within 15 min in purified water at 37°C under the conditions of Ph. Eur. 2.9.1, but enteric-coated tablets for intestinal delivery are tested in 0.1 M HCl for 2 h followed by phosphate buffer pH 6.8 according to Ph. Eur. 2.9.3. Uniformity of antigen content is assessed by ELISA on 10 tablets using Ph. Eur. 2.9.40 acceptance criteria; loss on tablet surfaces from punch picking is checked by visual inspection under 10x magnification. The tablet route is not suitable for live bacterial antigen unless the live component is microencapsulated; for inactivated E. coli vaccine API, the primary failure mode is antigen dose variability rather than cell death.

When E. coli antigen granules enter pelleted feed at 70–80°C, heat-labile surface antigens require recovery validation

Steam conditioning in feed mills is a serial heat and moisture shock that produces paste-like mash before extrusion through a die. In pig and poultry colibacillosis vaccination via feed, the E. coli antigen premix is often post-pellet coated rather than pre-mixed into the mash because standard conditioning temperatures of 65–85°C can denature protein surface antigens within 30–120 s of residence time. Published data for this specific antigen configuration is limited, so each feed mill installation is audited with a thermocouple probe placed after the conditioner and before the die to record actual product temperature rather than steam setpoint. The granules themselves are produced by fluid-bed top-spray granulation; binder solution viscosity is maintained below 50 mPa·s at 25°C to prevent nozzle blocking and agglomerate overgrowth. After drying, the granule fraction between 150 µm and 850 µm is selected for feed addition because finer material segregates to the bottom of mash bins and coarse material is visible to the animal and may be refused. Post-pellet application uses a horizontal paddle mixer or vacuum coater with a coefficient of variation for antigen tracer below 5.0% after 10 min of blending; samples are drawn from 10 locations in the mixer and tested by ELISA to confirm active antigen distribution.

Post-pellet vacuum coating is more complex than paddle blending but can be used when lipid coatings are needed to reduce antigen dust and improve adhesion to extruded feed pellets. The vacuum coater is operated at a pressure of 200 mbar absolute after pellets are heated to 35–40°C, and the antigen premix is sprayed through a binary nozzle with a droplet size below 100 µm. Coated pellets are dried by continued tumbling under vacuum; the final moisture is checked by infrared balance to stay below 12.0% w/w for storage in bulk bins. If moisture exceeds this limit, mold growth and antigen degradation can both occur. The process is not a simple dry blend: electrostatic charging of dusty antigen powder can cause adhesion to stainless-steel sidewalls, and relative humidity above 60% can hydrate fines and reduce flow through a screw conveyor. Premix must be protected from moisture by sealing in multi-wall bags with an inner polyethylene liner; opened bags are held at 20–25°C and used within 24 h to avoid water uptake.

Enteric Capsule Granulation and Gastric Bypass Geometry

E. coli antigen powders filled into hard capsules are rarely filled as loose powder because dose uniformity and enteric protection are poor. A granulated intermediate is produced by low-shear mixing and wet massing; the wet mass is forced through a 1.0 mm screen and dried in a fluid-bed dryer at inlet air temperature not exceeding 40°C to avoid thermal damage to the antigen. The dried granules are filled into size 3 or size 1 hard capsules on an automatic capsule machine with vacuum-pin separation. Filled capsule mass is checked at 15-minute intervals; individual weight variation must remain within ±5.0% of the target fill weight. Enteric protection is provided by a methacrylic acid copolymer coating applied in a pan coater; the coating thickness required to protect antigen against gastric fluid is verified by disintegration testing in 0.1 M HCl for 2 h with no capsule rupture, followed by release in phosphate buffer pH 6.8 according to Ph. Eur. 2.9.3. The geometry of gastric bypass is critical: capsules that float in the stomach may delay pyloric passage, whereas fast-sinking dense granules can be retained in the fundus. Therefore bulk density of the final granule is adjusted to between 0.55 g/cm³ and 0.75 g/cm³ by selecting the filler, and dissolution testing is performed with the capsule in a sinker.

Drinking-water administration of E. coli vaccine API is often treated as a simple dilution step, but the field risk originates in distribution-line chlorine and variable water hardness. The API is reconstituted into a stock solution in a central tank and then metered through a proportioner pump into drinking lines. If the water contains free chlorine at 0.2–1.0 mg/L, surface antigen proteins may oxidize rapidly; therefore chlorine neutralization with sodium thiosulfate is performed before API addition, and the water is retested for free chlorine with a DPD colorimetric kit before the vaccine is introduced. Hard water with calcium carbonate above 250 mg/L can produce sediment and reduce antigen suspension homogeneity. A buffered stabilizer containing phosphate salts and a nonionic surfactant is used to keep the antigen dispersed for at least 6 h after mixing; beyond this holding period, re-suspension is required and the stock solution should be stirred at low speed with an overhead impeller rather than a magnetic stir bar, which can settle cells into the dead volume of the tank.

The solution is not a true solution if whole-cell antigen is present; it is a suspension, and the proportioner pump must be calibrated for suspension flow with the actual stock rather than water. In-line proportioner pumps require separate validation for suspension because viscosity and particle settling alter the delivered volume. A flow verification test is performed by collecting water at the drinker outlet for 10 min and measuring antigen concentration by ELISA; the actual dose is then compared with the target. If the stock solution is held overnight, a low-speed impeller at 60 rpm is restarted at least 30 min before dosing. The distribution water pH is maintained between 6.0 and 7.0 if possible; alkaline pH above 8.0 can destabilize the suspension or reduce antigen availability. Stock solution is protected from sunlight and kept between 15–25°C; ultraviolet light and heat accelerate antigen degradation. The final in-use concentration is selected to deliver the target antigen mass per animal per day across 24 h of water intake, but actual water intake varies with ambient temperature, diet salt level, and disease status, so the in-line dosing must be adjusted based on measured water flow.